Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients (Q34637606)

3 August 2017

Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients (English)

1 reference

inflammatory bowel diseases

3 August 2017

0 references

0 references

0 references

0 references

1 reference

John Penders

2

0 references

Daisy M A E Jonkers

series ordinal

1

object named as

Daisy Jonkers

1 reference

3 August 2017

Ad Masclee

3

1 reference

PubMed ID

22512365

3 August 2017

Marieke Pierik

series ordinal

4

1 reference

3 August 2017

1 April 2012

1 reference

3 August 2017

1 reference

3 August 2017

72

1 reference

3 August 2017

6

1 reference

3 August 2017

803-823

1 reference

https://scigraph.springernature.com/pub.10.2165/11632710-000000000-00000

3 August 2017

0 references

cites work

Diversity of the human intestinal microbial flora

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

A human gut microbial gene catalogue established by metagenomic sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Enterotypes of the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Review article: the role of butyrate on colonic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Gut microbiota and the role of probiotics in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Obesity, metabolic syndrome, and microbiota: multiple interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Recent Insights Into the Genetics of Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

An update on the epidemiology of inflammatory bowel disease in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Molecular analysis of the gut microbiota of identical twins with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

In vitro alterations of intestinal bacterial microbiota in fecal samples during storage.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Low counts of Faecalibacterium prausnitzii in colitis microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Interactions between the host innate immune system and microbes in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Evolving knowledge and therapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Toll-like receptors in inflammatory bowel diseases: a decade later

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Intestinal epithelial cells in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

New IBD genetics: common pathways with other diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Reduced Paneth cell alpha-defensins in ileal Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Monostrain, multistrain and multispecies probiotics--A comparison of functionality and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Genes and molecules of lactobacilli supporting probiotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Unraveling mechanisms of action of probiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Mechanisms of probiotic actions - A review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

21 January 2018

Probiotics and immunity

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Lessons from probiotic-host interaction studies in murine models of experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotics: towards demonstrating efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

"Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Treatment of ulcerative colitis using fecal bacteriotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Effect of probiotics on intestinal barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Safety of industrial lactic acid bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Safety of probiotics: translocation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

Specificities of the fecal microbiota in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11632710-000000000-00000

TREATMENT OF ULCERATIVE COLITIS BY IMPLANTATION OF NORMAL COLONIC FLORA

21 January 2018

1 reference

12 December 2020

Ulcerative colitis with multidrug-resistant Pseudomonas aeruginosa infection successfully treated with bifidobacterium

1 reference

12 December 2020

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

1 reference

12 December 2020

Probiotics for induction of remission in ulcerative colitis

1 reference

12 December 2020

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

12 December 2020

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

1 reference

12 December 2020

Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability

1 reference

12 December 2020

High-dose probiotics for the treatment of active pouchitis

1 reference

12 December 2020

Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis

1 reference

12 December 2020

Mucosal bacteria in ulcerative colitis

1 reference

12 December 2020

Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment

1 reference

12 December 2020

The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls

1 reference

12 December 2020

The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis

1 reference

12 December 2020

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1 reference

12 December 2020

The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics

1 reference

12 December 2020

Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis

1 reference

12 December 2020

An evidence-based systematic review on medical therapies for inflammatory bowel disease

1 reference

12 December 2020

Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?

1 reference

12 December 2020

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

1 reference

12 December 2020

Role of stasis and oxidative stress in ileal pouch inflammation

1 reference

12 December 2020

Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection

1 reference

12 December 2020

Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis

1 reference

12 December 2020

Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

1 reference

12 December 2020

Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study

1 reference

12 December 2020

Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy

1 reference

12 December 2020

Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.

1 reference

12 December 2020

Organic anions and the diarrhea of inflammatory bowel disease

1 reference

12 December 2020

Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora

1 reference

12 December 2020

Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis

1 reference

12 December 2020

Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model

1 reference

12 December 2020

The role of the fecal stream in Crohn's disease: an historical and analytic review

1 reference

12 December 2020

10.2165/11632710-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22512365

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

22512365